Abstract：
OBJECTIVE: Our main goal of this meta-analytical analysis was to evaluate the diagnostic effectiveness of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) against multiparametric magnetic resonance imaging (mpMRI) in the context of identifying biochemical recurrence in patients with prostate cancer (PCa).
METHODS: A thorough search covering articles published until March 2023 was carried out across major databases such as PubMed, Embase, and Web of Science. Studies examining the direct comparison of PSMA PET/CT and mpMRI in patients with PCa suffering biochemical recurrence were included in the inclusion criteria. Using the renowned Quality Assessment of Diagnostic Performance Studies-2 technique, each study\'s methodological rigor was assessed.
RESULTS: We analyzed data from six eligible studies involving 290 patients in total. The combined data showed that for PSMA PET/CT and mpMRI, respectively, the pooled overall detection rates for recurrent PCa after definitive treatment were 0.69 (95% confidence interval [CI]: 0.45-0.89) and 0.70 (95% CI: 0.44-0.91). The detection rates for local recurrence were specifically 0.52 (95% CI: 0.39-0.65) and 0.62 (95% CI: 0.31-0.89), while they were 0.50 (95% CI: 0.26-0.74) and 0.32 (95% CI: 0.18-0.48) for lymph node metastasis. Notably, there was no discernible difference between the two imaging modalities in terms of the overall detection rate (P = 0.95). The detection rates for local recurrence and lymph node metastasis did not differ statistically significantly (P = 0.55, 0.23).
CONCLUSIONS: The performance of PSMA PET/CT and mpMRI in identifying biochemical recurrence in PCa appears to be comparable. However, the meta-analysis\' findings came from research with modest sample sizes. In this context, more extensive research should be conducted in the future.
METHODS: A thorough search covering articles published until March 2023 was carried out across major databases such as PubMed, Embase, and Web of Science. Studies examining the direct comparison of PSMA PET/CT and mpMRI in patients with PCa suffering biochemical recurrence were included in the inclusion criteria. Using the renowned Quality Assessment of Diagnostic Performance Studies-2 technique, each study\'s methodological rigor was assessed.
RESULTS: We analyzed data from six eligible studies involving 290 patients in total. The combined data showed that for PSMA PET/CT and mpMRI, respectively, the pooled overall detection rates for recurrent PCa after definitive treatment were 0.69 (95% confidence interval [CI]: 0.45-0.89) and 0.70 (95% CI: 0.44-0.91). The detection rates for local recurrence were specifically 0.52 (95% CI: 0.39-0.65) and 0.62 (95% CI: 0.31-0.89), while they were 0.50 (95% CI: 0.26-0.74) and 0.32 (95% CI: 0.18-0.48) for lymph node metastasis. Notably, there was no discernible difference between the two imaging modalities in terms of the overall detection rate (P = 0.95). The detection rates for local recurrence and lymph node metastasis did not differ statistically significantly (P = 0.55, 0.23).
CONCLUSIONS: The performance of PSMA PET/CT and mpMRI in identifying biochemical recurrence in PCa appears to be comparable. However, the meta-analysis\' findings came from research with modest sample sizes. In this context, more extensive research should be conducted in the future.
摘要：
目的：本荟萃分析的主要目的是评估前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）/计算机断层扫描（CT）对多参数磁共振成像（mpMRI）的诊断有效性在确定前列腺癌（PCa）患者的生化复发。
方法：在PubMed等主要数据库中进行了一次全面的搜索，搜索内容涵盖了直到2023年3月发表的文章，Embase,和WebofScience。纳入标准包括研究PSMAPET/CT和mpMRI对患有生化复发的PCa患者的直接比较。使用著名的诊断性能研究质量评估-2技术，评估了每项研究的方法学严谨性。
结果：我们分析了6项符合条件的研究数据，共涉及290名患者。综合数据显示，对于PSMAPET/CT和mpMRI，分别,明确治疗后复发PCa的合并总检出率分别为0.69(95%置信区间[CI]:0.45~0.89)和0.70(95%CI:0.44~0.91).局部复发的检出率分别为0.52(95%CI:0.39-0.65)和0.62(95%CI:0.31-0.89),而淋巴结转移为0.50（95％CI：0.26-0.74）和0.32（95％CI：0.18-0.48）。值得注意的是,两种成像方式在总体检出率方面没有明显差异(P=0.95).局部复发和淋巴结转移的检出率差异无统计学意义（P=0.55，0.23）。
结论：PSMAPET/CT和mpMRI在识别PCa生化复发方面的表现似乎相当。然而,荟萃分析的结果来自样本量适中的研究。在这种情况下，未来应该进行更广泛的研究。
方法：在PubMed等主要数据库中进行了一次全面的搜索，搜索内容涵盖了直到2023年3月发表的文章，Embase,和WebofScience。纳入标准包括研究PSMAPET/CT和mpMRI对患有生化复发的PCa患者的直接比较。使用著名的诊断性能研究质量评估-2技术，评估了每项研究的方法学严谨性。
结果：我们分析了6项符合条件的研究数据，共涉及290名患者。综合数据显示，对于PSMAPET/CT和mpMRI，分别,明确治疗后复发PCa的合并总检出率分别为0.69(95%置信区间[CI]:0.45~0.89)和0.70(95%CI:0.44~0.91).局部复发的检出率分别为0.52(95%CI:0.39-0.65)和0.62(95%CI:0.31-0.89),而淋巴结转移为0.50（95％CI：0.26-0.74）和0.32（95％CI：0.18-0.48）。值得注意的是,两种成像方式在总体检出率方面没有明显差异(P=0.95).局部复发和淋巴结转移的检出率差异无统计学意义（P=0.55，0.23）。
结论：PSMAPET/CT和mpMRI在识别PCa生化复发方面的表现似乎相当。然而,荟萃分析的结果来自样本量适中的研究。在这种情况下，未来应该进行更广泛的研究。
